首页 > 最新文献

Korean Journal of Internal Medicine最新文献

英文 中文
Decompensated cirrhosis and antibiotic prophylaxis: striking a delicate balance. 失代偿期肝硬化与抗生素预防:取得微妙的平衡。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.3904/kjim.2024.119
Jung Gil Park
{"title":"Decompensated cirrhosis and antibiotic prophylaxis: striking a delicate balance.","authors":"Jung Gil Park","doi":"10.3904/kjim.2024.119","DOIUrl":"10.3904/kjim.2024.119","url":null,"abstract":"","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"39 3","pages":"369-370"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From pinprick to peril: digital ischemia and necrosis of fingertips induced by routine capillary glucose testing. 从针刺到危险:常规毛细血管葡萄糖检测引起的指尖缺血和坏死。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 Epub Date: 2024-01-26 DOI: 10.3904/kjim.2023.370
Wan-Hee Yoo, Yunjung Choi
{"title":"From pinprick to peril: digital ischemia and necrosis of fingertips induced by routine capillary glucose testing.","authors":"Wan-Hee Yoo, Yunjung Choi","doi":"10.3904/kjim.2023.370","DOIUrl":"10.3904/kjim.2023.370","url":null,"abstract":"","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"541-542"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139563890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementing antimicrobial stewardship: lessons and perspectives from a university-affiliated tertiary hospital in Korea. 实施抗菌药物管理:韩国一所大学附属三级医院的经验和观点。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.3904/kjim.2023.504
Soo Jin Lee, Raeseok Lee, Sung-Yeon Cho, Dukhee Nho, Hye Lim Ahn, Dong-Gun Lee

Antimicrobial stewardship programs (ASPs) can lower antibiotic use, decrease medical expenses, prevent the emergence of resistant bacteria, and enhance treatment for infectious diseases. This study summarizes the stepwise implementation and effects of ASPs in a single university-affiliated tertiary care hospital in Korea; it also presents future directions and challenges in resource-limited settings. At the study hospital, the core elements of the ASP such as leadership commitment, accountability, and operating system were established in 2000, then strengthened by the formation of the Antimicrobial Stewardship (AMS) Team in 2018. The actions of ASPs entail key components including a computerized restrictive antibiotic prescription system, prospective audit, post-prescription review through quantitative and qualitative intervention, and pharmacy-based interventions to optimize antibiotic usage. The AMS Team regularly tracked antibiotic use, the effects of interventions, and the resistance patterns of pathogens in the hospital. The reporting system was enhanced and standardized by participation in the Korea National Antimicrobial Use Analysis System, and educational efforts are ongoing. Stepwise implementation of the ASP and the efforts of the AMS Team have led to a substantial reduction in the overall consumption of antibiotics, particularly regarding injectables, and optimization of antibiotic use. Our experience highlights the importance of leadership, accountability, institution-specific interventions, and the AMS Team.

抗菌药物管理计划(ASP)可以降低抗生素的使用量、减少医疗费用、防止耐药菌的出现并提高传染病的治疗效果。本研究总结了抗菌药物管理计划在韩国一家大学附属三级医院的逐步实施情况和效果,同时也提出了在资源有限的环境中未来的发展方向和挑战。该研究医院于 2000 年建立了 ASP 的核心要素,如领导承诺、问责制和运行系统,并于 2018 年成立了抗菌药物管理团队(AMS),从而加强了 ASP 的核心要素。ASP 的行动需要包括计算机化的限制性抗生素处方系统、前瞻性审计、通过定量和定性干预进行处方后审查,以及基于药房的优化抗生素使用干预等关键组成部分。AMS 团队定期跟踪抗生素的使用情况、干预措施的效果以及医院病原体的耐药性模式。通过加入韩国国家抗菌药物使用分析系统,报告系统得到了加强和规范,教育工作也在持续进行中。通过逐步实施 ASP 和 AMS 小组的努力,抗生素的总用量(尤其是注射用抗生素)大幅减少,抗生素的使用也得到了优化。我们的经验凸显了领导力、问责制、针对特定机构的干预措施以及 AMS 团队的重要性。
{"title":"Implementing antimicrobial stewardship: lessons and perspectives from a university-affiliated tertiary hospital in Korea.","authors":"Soo Jin Lee, Raeseok Lee, Sung-Yeon Cho, Dukhee Nho, Hye Lim Ahn, Dong-Gun Lee","doi":"10.3904/kjim.2023.504","DOIUrl":"10.3904/kjim.2023.504","url":null,"abstract":"<p><p>Antimicrobial stewardship programs (ASPs) can lower antibiotic use, decrease medical expenses, prevent the emergence of resistant bacteria, and enhance treatment for infectious diseases. This study summarizes the stepwise implementation and effects of ASPs in a single university-affiliated tertiary care hospital in Korea; it also presents future directions and challenges in resource-limited settings. At the study hospital, the core elements of the ASP such as leadership commitment, accountability, and operating system were established in 2000, then strengthened by the formation of the Antimicrobial Stewardship (AMS) Team in 2018. The actions of ASPs entail key components including a computerized restrictive antibiotic prescription system, prospective audit, post-prescription review through quantitative and qualitative intervention, and pharmacy-based interventions to optimize antibiotic usage. The AMS Team regularly tracked antibiotic use, the effects of interventions, and the resistance patterns of pathogens in the hospital. The reporting system was enhanced and standardized by participation in the Korea National Antimicrobial Use Analysis System, and educational efforts are ongoing. Stepwise implementation of the ASP and the efforts of the AMS Team have led to a substantial reduction in the overall consumption of antibiotics, particularly regarding injectables, and optimization of antibiotic use. Our experience highlights the importance of leadership, accountability, institution-specific interventions, and the AMS Team.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"39 3","pages":"399-412"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis. 肝硬化患者耐多药菌血症的发生率和预测因素。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.3904/kjim.2023.354
Aryoung Kim, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh

Background/aims: Improved knowledge of local epidemiology and predicting risk factors of multidrug-resistant (MDR) bacteria are required to optimize the management of infections. This study examined local epidemiology and antibiotic resistance patterns of liver cirrhosis (LC) patients and evaluated the predictors of MDR bacteremia in Korea.

Methods: This was a retrospective study including 140 LC patients diagnosed with bacteremia between January 2017 and December 2022. Local epidemiology and antibiotic resistance patterns and the determinants of MDR bacteremia were analyzed using logistic regression analysis.

Results: The most frequently isolated bacteria, from the bloodstream, were Escherichia coli (n = 45, 31.7%) and Klebsiella spp. (n = 35, 24.6%). Thirty-four isolates (23.9%) were MDR, and extended-spectrum beta-lactamase E. coli (52.9%) and methicillin-resistant Staphylococcus aureus (17.6%) were the most commonly isolated MDR bacteria. When Enterococcus spp. were cultured, the majority were MDR (MDR 83.3% vs. 16.7%, p = 0.003), particularly vancomycin-susceptible Enterococcus faecium. Antibiotics administration within 30 days and/or nosocomial infection was a significant predictor of MDR bacteremia (OR: 3.40, 95% CI: 1.24-9.27, p = 0.02). MDR bacteremia was not predicted by sepsis predictors, such as positive systemic inflammatory response syndrome (SIRS) or quick Sequential Organ Failure Assessment (qSOFA).

Conclusion: More than 70% of strains that can be treated with a third-generation cephalosporin have been cultured. In cirrhotic patients, antibiotic administration within 30 days and/or nosocomial infection are predictors of MDR bacteremia; therefore, empirical administration of broad-spectrum antibiotics should be considered when these risk factors are present.

背景/目的:为了优化感染管理,需要进一步了解当地流行病学并预测耐多药(MDR)细菌的风险因素。本研究调查了韩国肝硬化(LC)患者的地方流行病学和抗生素耐药模式,并评估了多重耐药菌血症的预测因素:这是一项回顾性研究,包括2017年1月至2022年12月期间确诊为菌血症的140名肝硬化患者。采用逻辑回归分析法对当地流行病学和抗生素耐药模式以及 MDR 菌血症的决定因素进行了分析:从血液中分离出的最常见细菌是大肠埃希菌(45 株,31.7%)和克雷伯菌属(35 株,24.6%)。34个分离菌株(23.9%)具有耐甲氧西林耐药菌株(MDR),大肠埃希菌(52.9%)和耐甲氧西林金黄色葡萄球菌(17.6%)是最常见的耐甲氧西林耐药菌株。当培养出肠球菌属时,大多数都是 MDR(MDR 83.3% vs. 16.7%,p = 0.003),尤其是对万古霉素敏感的粪肠球菌。30 天内使用抗生素和/或院内感染是 MDR 菌血症的重要预测因素(OR:3.40,95% CI:1.24-9.27,p = 0.02)。脓毒症预测因子,如阳性全身炎症反应综合征(SIRS)或快速序贯器官衰竭评估(qSOFA)并不能预测 MDR 菌血症:结论:超过 70% 的菌株可通过第三代头孢菌素治疗。在肝硬化患者中,30 天内使用抗生素和/或院内感染是 MDR 菌血症的预测因素;因此,当存在这些风险因素时,应考虑经验性使用广谱抗生素。
{"title":"Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis.","authors":"Aryoung Kim, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh","doi":"10.3904/kjim.2023.354","DOIUrl":"10.3904/kjim.2023.354","url":null,"abstract":"<p><strong>Background/aims: </strong>Improved knowledge of local epidemiology and predicting risk factors of multidrug-resistant (MDR) bacteria are required to optimize the management of infections. This study examined local epidemiology and antibiotic resistance patterns of liver cirrhosis (LC) patients and evaluated the predictors of MDR bacteremia in Korea.</p><p><strong>Methods: </strong>This was a retrospective study including 140 LC patients diagnosed with bacteremia between January 2017 and December 2022. Local epidemiology and antibiotic resistance patterns and the determinants of MDR bacteremia were analyzed using logistic regression analysis.</p><p><strong>Results: </strong>The most frequently isolated bacteria, from the bloodstream, were Escherichia coli (n = 45, 31.7%) and Klebsiella spp. (n = 35, 24.6%). Thirty-four isolates (23.9%) were MDR, and extended-spectrum beta-lactamase E. coli (52.9%) and methicillin-resistant Staphylococcus aureus (17.6%) were the most commonly isolated MDR bacteria. When Enterococcus spp. were cultured, the majority were MDR (MDR 83.3% vs. 16.7%, p = 0.003), particularly vancomycin-susceptible Enterococcus faecium. Antibiotics administration within 30 days and/or nosocomial infection was a significant predictor of MDR bacteremia (OR: 3.40, 95% CI: 1.24-9.27, p = 0.02). MDR bacteremia was not predicted by sepsis predictors, such as positive systemic inflammatory response syndrome (SIRS) or quick Sequential Organ Failure Assessment (qSOFA).</p><p><strong>Conclusion: </strong>More than 70% of strains that can be treated with a third-generation cephalosporin have been cultured. In cirrhotic patients, antibiotic administration within 30 days and/or nosocomial infection are predictors of MDR bacteremia; therefore, empirical administration of broad-spectrum antibiotics should be considered when these risk factors are present.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"39 3","pages":"448-457"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to 2022 ACR/EULAR criteria. 根据 2022 年 ACR/EULAR 标准,系统性硬化症与抗中性粒细胞胞浆抗体相关性血管炎重叠综合征。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 Epub Date: 2024-01-29 DOI: 10.3904/kjim.2023.189
Jang Woo Ha, Jung Yoon Pyo, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee

Background/aims: This study applied the 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to patients with systemic sclerosis (SSc) and investigated the frequency of overlap syndrome of SSc and AAV (SSc-AAV-OS).

Methods: Among the 232 patients diagnosed with SSc, 105 with signs suggestive of small- or medium-vessel vasculitis, which were defined as the present of interstitial lung disease (ILD), peripheral neuropathy, or suspected renal vasculitis, were included in this study and analyzed.

Results: Among the 105 SSc patients, the detection rate of ANCA was 19.0%. When the 2022 ACR/EULAR criteria were applied, the frequency of SSc-AAV-OS was 20.0%, which was much higher than 1.7% reported with previous criteria for AAV. ANCA positivity contributed to the reclassification of SSc-AAV-OS more than ANCA negativity in SSc patients with signs suggestive of small- or medium-vessel vasculitis.

Conclusion: The frequency of SSc-AAV-OS in SSc patients with signs suggestive of small- or medium-vessel vasculitis at diagnosis was 20.0%. Therefore, we suggest that physicians should perform ANCA tests in SSc patients exhibiting signs suggestive of small- or medium-vessel vasculitis and apply the new criteria for AAV.

背景/目的:这项研究将2022年美国风湿病学会(ACR)/欧洲风湿病学协会联盟(EULAR)的抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)标准应用于系统性硬化症(SSc)患者,并调查SSc与AAV(SSc-AAV-OS)重叠综合征的发生频率:方法:在232名确诊为SSc的患者中,有105名患者出现了提示中小血管炎的体征,即出现间质性肺病(ILD)、周围神经病变或疑似肾血管炎,本研究对这些患者进行了分析:在105名SSc患者中,ANCA的检出率为19.0%。当采用 2022 年 ACR/EULAR 标准时,SSc-AAV-OS 的发生率为 20.0%,远高于以往 AAV 标准下的 1.7%。在有中小血管炎体征的SSc患者中,ANCA阳性比ANCA阴性更有助于SSc-AAV-OS的重新分类:在确诊时有中小血管炎体征的 SSc 患者中,SSc-AAV-OS 的发生率为 20.0%。因此,我们建议医生对有中小血管炎体征的 SSc 患者进行 ANCA 检测,并应用 AAV 的新标准。
{"title":"Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to 2022 ACR/EULAR criteria.","authors":"Jang Woo Ha, Jung Yoon Pyo, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee","doi":"10.3904/kjim.2023.189","DOIUrl":"10.3904/kjim.2023.189","url":null,"abstract":"<p><strong>Background/aims: </strong>This study applied the 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to patients with systemic sclerosis (SSc) and investigated the frequency of overlap syndrome of SSc and AAV (SSc-AAV-OS).</p><p><strong>Methods: </strong>Among the 232 patients diagnosed with SSc, 105 with signs suggestive of small- or medium-vessel vasculitis, which were defined as the present of interstitial lung disease (ILD), peripheral neuropathy, or suspected renal vasculitis, were included in this study and analyzed.</p><p><strong>Results: </strong>Among the 105 SSc patients, the detection rate of ANCA was 19.0%. When the 2022 ACR/EULAR criteria were applied, the frequency of SSc-AAV-OS was 20.0%, which was much higher than 1.7% reported with previous criteria for AAV. ANCA positivity contributed to the reclassification of SSc-AAV-OS more than ANCA negativity in SSc patients with signs suggestive of small- or medium-vessel vasculitis.</p><p><strong>Conclusion: </strong>The frequency of SSc-AAV-OS in SSc patients with signs suggestive of small- or medium-vessel vasculitis at diagnosis was 20.0%. Therefore, we suggest that physicians should perform ANCA tests in SSc patients exhibiting signs suggestive of small- or medium-vessel vasculitis and apply the new criteria for AAV.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"524-536"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modified application of SAMe-TT2R2 scoring system in Asian patients with atrial fibrillation for the selection of oral anticoagulants. 在亚洲心房颤动患者中修改应用 SAMe-TT2R2 评分系统以选择口服抗凝剂。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 Epub Date: 2024-01-30 DOI: 10.3904/kjim.2023.381
Seong Won Jeon, Nuri Lee, Ki Hong Lee, Minjeong Ha, Changhyun Kim, Yoo Ri Kim, Nam Sik Yoon, Hyung Wook Park

Background/aims: The SAMe-TT2R2 score is used for assessing anticoagulation control (AC) quality with warfarin. However, it is hard to apply SAMe-TT2R2 score in Asian patients with atrial fibrillation (AF), because it has not been proven in those populations. This study aimed to validate the SAMe-TT2R2 score in Asian patients with AF and suggest a modified SAMe- TT2R2 score for this population.

Methods: We analyzed 710 Korean patients with AF who were using warfarin. The AC quality was assessed as the mean time in therapeutic range (TTR). Each component of SAMe-TT2R2 score was evaluated for the relationship with AC. Further clinical factors that predict AC were analyzed. Identified factors were re-assorted and constructed as SA2Me-TTR scoring system.

Results: Of the components of the SAMe-TT2R2 score, female, age, and rhythm control were associated with AC. Heart failure and renal insufficiency were newly identified factors associated with AC. The modified SA2Me-TTR score was reconstructed with the relevant risk factors (S, female gender, 1 point; A, age < 60 yr, 2 points; Me, medical history of heart failure, 1 point; T, treatment for rhythm control, 1 point; T, history of stroke or transient ischemic attack, 1 point; R, renal insufficiency, 1 point). The modified SA2Me-TTR score demonstrated an excellent relationship with the grading of AC. The modified SA2Me-TTR score ≤ 1 identified patients with good AC (hazard ratio 2.46, 95% CI 1.75-3.47).

Conclusion: The modified SA2Me-TTR score was useful for guiding oral anticoagulants selection in Asian patients with AF.

背景/目的:SAMe-TT2R2 评分用于评估华法林的抗凝控制(AC)质量。然而,由于 SAMe-TT2R2 评分尚未在亚洲心房颤动(房颤)患者中得到证实,因此很难在这些人群中应用。本研究旨在验证亚洲房颤患者的 SAMe-TT2R2 评分,并提出适用于该人群的改良 SAMe-TT2R2 评分:我们分析了710名使用华法林的韩国房颤患者。交流质量以治疗范围内的平均时间(TTR)进行评估。评估了 SAMe-TT2R2 评分的每个组成部分与 AC 的关系。此外,还分析了预测 AC 的其他临床因素。对确定的因素进行了重新分类,并构建了 SA2Me-TTR 评分系统:结果:在 SAMe-TT2R2 评分的组成部分中,女性、年龄和节律控制与 AC 相关。而心力衰竭和肾功能不全则是新发现的与 AC 相关的因素。改良的 SA2Me-TTR 评分与相关风险因素(S,女性,1 分;A,年龄小于 60 岁,2 分;Me,心衰病史,1 分;T,心律控制治疗,1 分;T,中风或短暂性脑缺血发作病史,1 分;R,肾功能不全,1 分)进行了重构。改良的 SA2Me-TTR 评分与 AC 的分级有很好的关系。修改后的 SA2Me-TTR 评分≤1 分可识别出 AC 良好的患者(危险比 2.46,95% CI 1.75-3.47):修改后的SA2Me-TTR评分有助于指导亚洲房颤患者选择口服抗凝药。
{"title":"Modified application of SAMe-TT2R2 scoring system in Asian patients with atrial fibrillation for the selection of oral anticoagulants.","authors":"Seong Won Jeon, Nuri Lee, Ki Hong Lee, Minjeong Ha, Changhyun Kim, Yoo Ri Kim, Nam Sik Yoon, Hyung Wook Park","doi":"10.3904/kjim.2023.381","DOIUrl":"10.3904/kjim.2023.381","url":null,"abstract":"<p><strong>Background/aims: </strong>The SAMe-TT2R2 score is used for assessing anticoagulation control (AC) quality with warfarin. However, it is hard to apply SAMe-TT2R2 score in Asian patients with atrial fibrillation (AF), because it has not been proven in those populations. This study aimed to validate the SAMe-TT2R2 score in Asian patients with AF and suggest a modified SAMe- TT2R2 score for this population.</p><p><strong>Methods: </strong>We analyzed 710 Korean patients with AF who were using warfarin. The AC quality was assessed as the mean time in therapeutic range (TTR). Each component of SAMe-TT2R2 score was evaluated for the relationship with AC. Further clinical factors that predict AC were analyzed. Identified factors were re-assorted and constructed as SA2Me-TTR scoring system.</p><p><strong>Results: </strong>Of the components of the SAMe-TT2R2 score, female, age, and rhythm control were associated with AC. Heart failure and renal insufficiency were newly identified factors associated with AC. The modified SA2Me-TTR score was reconstructed with the relevant risk factors (S, female gender, 1 point; A, age < 60 yr, 2 points; Me, medical history of heart failure, 1 point; T, treatment for rhythm control, 1 point; T, history of stroke or transient ischemic attack, 1 point; R, renal insufficiency, 1 point). The modified SA2Me-TTR score demonstrated an excellent relationship with the grading of AC. The modified SA2Me-TTR score ≤ 1 identified patients with good AC (hazard ratio 2.46, 95% CI 1.75-3.47).</p><p><strong>Conclusion: </strong>The modified SA2Me-TTR score was useful for guiding oral anticoagulants selection in Asian patients with AF.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"458-468"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139576655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of biomarkers in antimicrobial stewardship: physicians' perspectives. 生物标志物在抗菌药物管理中的作用:医生的观点。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.3904/kjim.2023.558
Hyeri Seok, Dae Won Park

Biomarkers are playing an increasingly important role in antimicrobial stewardship. Their applications have included use in algorithms that evaluate suspected bacterial infections or provide guidance on when to start or stop antibiotic therapy, or when therapy should be repeated over a short period (6-12 h). Diseases in which biomarkers are used as complementary tools to determine the initiation of antibiotics include sepsis, lower respiratory tract infection (LRTI), COVID-19, acute heart failure, infectious endocarditis, acute coronary syndrome, and acute pancreatitis. In addition, cut-off values of biomarkers have been used to inform the decision to discontinue antibiotics for diseases such as sepsis, LRTI, and febrile neutropenia. The biomarkers used in antimicrobial stewardship include procalcitonin (PCT), C-reactive protein (CRP), presepsin, and interleukin (IL)-1β/IL-8. The cut-off values vary depending on the disease and study, with a range of 0.25-1.0 ng/mL for PCT and 8-50 mg/L for CRP. Biomarkers can complement clinical diagnosis, but further studies of microbiological biomarkers are needed to ensure appropriate antibiotic selection.

生物标志物在抗菌药物管理中发挥着越来越重要的作用。生物标志物的应用包括在评估疑似细菌感染的算法中使用,或为何时开始或停止抗生素治疗或何时应在短期内(6-12 小时)重复治疗提供指导。生物标志物可作为辅助工具用于确定是否开始使用抗生素的疾病包括败血症、下呼吸道感染(LRTI)、COVID-19、急性心力衰竭、感染性心内膜炎、急性冠状动脉综合征和急性胰腺炎。此外,生物标志物的临界值还被用于为败血症、下呼吸道感染和发热性中性粒细胞减少症等疾病停用抗生素的决定提供依据。抗菌药物管理中使用的生物标志物包括降钙素原(PCT)、C 反应蛋白(CRP)、前蛋白酶和白细胞介素(IL)-1β/IL-8。临界值因疾病和研究而异,PCT 为 0.25-1.0 纳克/毫升,CRP 为 8-50 毫克/升。生物标志物可以补充临床诊断,但需要进一步研究微生物生物标志物,以确保选择适当的抗生素。
{"title":"Role of biomarkers in antimicrobial stewardship: physicians' perspectives.","authors":"Hyeri Seok, Dae Won Park","doi":"10.3904/kjim.2023.558","DOIUrl":"10.3904/kjim.2023.558","url":null,"abstract":"<p><p>Biomarkers are playing an increasingly important role in antimicrobial stewardship. Their applications have included use in algorithms that evaluate suspected bacterial infections or provide guidance on when to start or stop antibiotic therapy, or when therapy should be repeated over a short period (6-12 h). Diseases in which biomarkers are used as complementary tools to determine the initiation of antibiotics include sepsis, lower respiratory tract infection (LRTI), COVID-19, acute heart failure, infectious endocarditis, acute coronary syndrome, and acute pancreatitis. In addition, cut-off values of biomarkers have been used to inform the decision to discontinue antibiotics for diseases such as sepsis, LRTI, and febrile neutropenia. The biomarkers used in antimicrobial stewardship include procalcitonin (PCT), C-reactive protein (CRP), presepsin, and interleukin (IL)-1β/IL-8. The cut-off values vary depending on the disease and study, with a range of 0.25-1.0 ng/mL for PCT and 8-50 mg/L for CRP. Biomarkers can complement clinical diagnosis, but further studies of microbiological biomarkers are needed to ensure appropriate antibiotic selection.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"39 3","pages":"413-429"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study. 弥漫大 B 细胞淋巴瘤老年患者的老年风险模型(GERIAD):一项前瞻性多中心队列研究。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 Epub Date: 2024-01-30 DOI: 10.3904/kjim.2023.265
Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak

Background/aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).

Methods: This multicenter prospective cohort study enrolled newly diagnosed patients with DLBCL (≥ 65 yr) between September 2015 and April 2018. A simplified geriatric assessment was performed at baseline using Activities of Daily Living (ADL), Instrumental ADL (IADL), and Charlson's Comorbidity Index (CCI). The primary endpoint was event-free survival (EFS).

Results: The study included 249 patients, the median age was 74 years (range, 65-88), and 125 (50.2%) were female. In multivariable Cox analysis, ADL, IADL, CCI, and age were independent factors for EFS; an integrated geriatric score was derived and the patients stratified into three geriatric categories: fit (n = 162, 65.1%), intermediate-fit (n = 25, 10.0%), and frail (n = 62, 24.9%). The established geriatric model was significantly associated with EFS (fit vs. intermediate-fit, HR 2.61, p < 0.001; fit vs. frail, HR 4.61, p < 0.001) and outperformed each covariate alone or in combination. In 87 intermediate-fit or frail patients, the relative doxorubicin dose intensity (RDDI) ≥ 62.4% was significantly associated with worse EFS (HR, 2.15, 95% CI 1.30-3.53, p = 0.002). It was related with a higher incidence of grade ≥ 3 symptomatic non-hematologic toxicities (63.2% vs. 27.8%, p < 0.001) and earlier treatment discontinuation (34.5% vs. 8.0%, p < 0.001) in patients with RDDI ≥ 62.4% than in those with RDDI < 62.4%.

Conclusion: This model integrating simplified geriatric assessment can risk-stratify older patients with DLBCL and identify those who are highly vulnerable to standard dose-intensity chemoimmunotherapy.

背景/摘要在弥漫大B细胞淋巴瘤(DLBCL)老年患者中,需要明确基于简化老年评估的最佳风险分层,以预测治疗相关毒性和生存率:这项多中心前瞻性队列研究招募了2015年9月至2018年4月期间新确诊的DLBCL患者(≥65岁)。基线时使用日常生活活动能力(ADL)、工具性日常生活活动能力(IADL)和查尔森合并症指数(CCI)进行简化老年评估。主要终点是无事件生存期(EFS):研究共纳入 249 名患者,中位年龄为 74 岁(65-88 岁),女性 125 人(50.2%)。在多变量 Cox 分析中,ADL、IADL、CCI 和年龄是影响无事件生存期的独立因素;得出了综合老年病学评分,并将患者分为三个老年病学类别:体格健壮(n = 162,65.1%)、中等体格(n = 25,10.0%)和体弱(n = 62,24.9%)。已建立的老年医学模型与 EFS 显著相关(体格健壮 vs. 中等体格健壮,HR 2.61,p < 0.001;体格健壮 vs. 体弱多病,HR 4.61,p < 0.001),并且优于每个单独或组合的协变量。在87名体质中等或虚弱的患者中,多柔比星相对剂量强度(RDDI)≥ 62.4%与较差的EFS显著相关(HR,2.15,95% CI 1.30-3.53,p = 0.002)。与RDDI<62.4%的患者相比,RDDI≥62.4%的患者发生≥3级症状性非血液学毒性(63.2% vs. 27.8%,p<0.001)和更早停止治疗(34.5% vs. 8.0%,p<0.001)的几率更高:该模型整合了简化的老年评估,可对老年DLBCL患者进行风险分层,并识别出那些极易受到标准剂量强度化疗免疫疗法影响的患者。
{"title":"Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.","authors":"Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak","doi":"10.3904/kjim.2023.265","DOIUrl":"10.3904/kjim.2023.265","url":null,"abstract":"<p><strong>Background/aims: </strong>Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>This multicenter prospective cohort study enrolled newly diagnosed patients with DLBCL (≥ 65 yr) between September 2015 and April 2018. A simplified geriatric assessment was performed at baseline using Activities of Daily Living (ADL), Instrumental ADL (IADL), and Charlson's Comorbidity Index (CCI). The primary endpoint was event-free survival (EFS).</p><p><strong>Results: </strong>The study included 249 patients, the median age was 74 years (range, 65-88), and 125 (50.2%) were female. In multivariable Cox analysis, ADL, IADL, CCI, and age were independent factors for EFS; an integrated geriatric score was derived and the patients stratified into three geriatric categories: fit (n = 162, 65.1%), intermediate-fit (n = 25, 10.0%), and frail (n = 62, 24.9%). The established geriatric model was significantly associated with EFS (fit vs. intermediate-fit, HR 2.61, p < 0.001; fit vs. frail, HR 4.61, p < 0.001) and outperformed each covariate alone or in combination. In 87 intermediate-fit or frail patients, the relative doxorubicin dose intensity (RDDI) ≥ 62.4% was significantly associated with worse EFS (HR, 2.15, 95% CI 1.30-3.53, p = 0.002). It was related with a higher incidence of grade ≥ 3 symptomatic non-hematologic toxicities (63.2% vs. 27.8%, p < 0.001) and earlier treatment discontinuation (34.5% vs. 8.0%, p < 0.001) in patients with RDDI ≥ 62.4% than in those with RDDI < 62.4%.</p><p><strong>Conclusion: </strong>This model integrating simplified geriatric assessment can risk-stratify older patients with DLBCL and identify those who are highly vulnerable to standard dose-intensity chemoimmunotherapy.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"501-512"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139576628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The significance of ophthalmologic examination in a patient with xanthoma. 黄疽患者眼科检查的意义。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-03-01 Epub Date: 2023-12-22 DOI: 10.3904/kjim.2023.346
In Sun Goak, Seol A Jang, Yu Jin Jin, In-Cheon You, Ji Hyun Park
{"title":"The significance of ophthalmologic examination in a patient with xanthoma.","authors":"In Sun Goak, Seol A Jang, Yu Jin Jin, In-Cheon You, Ji Hyun Park","doi":"10.3904/kjim.2023.346","DOIUrl":"10.3904/kjim.2023.346","url":null,"abstract":"","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"362-363"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nighttime administration of antihypertensive medication: a review of chronotherapy in hypertension. 夜间给药降压药:高血压的时间疗法综述。
IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-03-01 Epub Date: 2023-11-16 DOI: 10.3904/kjim.2023.304
Hyun-Jin Kim, Sang-Ho Jo

Hypertension remains a global health concern because of suboptimal blood pressure control despite advancements in antihypertensive treatments. Chronotherapy, defined as evening or bedtime administration of medication based on biological rhythms, is emerging as a potential strategy to improve blood pressure control and treatment outcomes. Clinical trials have investigated the potential effects of nighttime administration of antihypertensive medication in the improvement of 24 hours blood pressure control and reduction of cardiovascular risk. Implementing chronotherapy in clinical practice could have significant implications in enhancing blood pressure control and improving clinical outcomes in patients with hypertension, particularly those with resistant hypertension. However, recent trials have reported contradictory results, causing confusion in real-world practice. Herein we review, analyze, and critique the current evidence and propose suggestions regarding the clinical application and future directions of chronotherapy.

尽管降压治疗取得了进展,但由于血压控制欠佳,高血压仍然是一个全球性的健康问题。时间疗法被定义为根据生物节律在晚上或睡前给药,它正在成为一种改善血压控制和治疗效果的潜在策略。临床试验研究了夜间服用降压药在改善24小时血压控制和降低心血管风险方面的潜在作用。在临床实践中实施时间疗法可能对高血压患者,特别是顽固性高血压患者加强血压控制和改善临床结果具有重要意义。然而,最近的试验报告了相互矛盾的结果,在现实世界的实践中造成了混乱。在此,我们回顾、分析和批判目前的证据,并就时间疗法的临床应用和未来方向提出建议。
{"title":"Nighttime administration of antihypertensive medication: a review of chronotherapy in hypertension.","authors":"Hyun-Jin Kim, Sang-Ho Jo","doi":"10.3904/kjim.2023.304","DOIUrl":"10.3904/kjim.2023.304","url":null,"abstract":"<p><p>Hypertension remains a global health concern because of suboptimal blood pressure control despite advancements in antihypertensive treatments. Chronotherapy, defined as evening or bedtime administration of medication based on biological rhythms, is emerging as a potential strategy to improve blood pressure control and treatment outcomes. Clinical trials have investigated the potential effects of nighttime administration of antihypertensive medication in the improvement of 24 hours blood pressure control and reduction of cardiovascular risk. Implementing chronotherapy in clinical practice could have significant implications in enhancing blood pressure control and improving clinical outcomes in patients with hypertension, particularly those with resistant hypertension. However, recent trials have reported contradictory results, causing confusion in real-world practice. Herein we review, analyze, and critique the current evidence and propose suggestions regarding the clinical application and future directions of chronotherapy.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"205-214"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Korean Journal of Internal Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1